HopeStage
Back to all studies
CompletedNCT00664703

Lobeline, methylphenidate or placebo for adult ADHD

About this titleRead the official source — NCT00664703
Medication studyAges 21–45United States
The study in practice

Understand this study

Who was this study for?

Listed age limits: 21 years to 45 years.

What did participation involve?

The protocol includes: Completing questionnaires.

Listed locations
LexingtonSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateJuly 2008
Recruitment status
Completed
Enrollment listed in the registry
13
Sponsor
Yaupon Therapeutics
Sponsor type
Biotech company
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 21 Years to 45 Years
Official registry ID
NCT00664703
Official title
Show the full official title

A Double-Blind, Double-Dummy, Placebo-Controlled, Dose Ranging Study of 7.5, 15, and 30 mg of Sublingual Lobeline in Adult ADHD Patients

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Lexington

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What did participation involve?

The protocol called for participants to complete questionnaires.

Who is behind this study?

The study sponsor is Yaupon Therapeutics.

Did this study involve medication?

Yes. The study involved medication, including Lobeline sulfate, Methylphenidate HCl and Placebo.

Who was this study for?

Listed age limits: 21 years to 45 years.

Want to explore more studies?

Explore studies